Predict your next investment

Antidote company logo
INTERNET | Internet Software & Services / Search
antidote.me

See what CB Insights has to offer

Executives

6

Board of Directors

2

Antidote Board of Directors

2 Board of directors

Antidote has 2 board of directors, including Francesca Wuttke.

Name

Firm

Work History

Other Seats

Francesca Wuttke

Broad drug development expertise with over 20 years of commercial, strategic and transactional experience from private equity, management consulting, BD&L and technology licensing and from co-founding Asten BioPharma Advisors, a New York City based healthcare consultancy. PhD in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a BA from Cornell University College of Arts and Sciences. Experience in both science and business has provided proficiency in multiple areas of the pharmaceutical and biotechnology industry including opportunity assessment and selection, product diligence, primary and secondary market research, sales forecasting, market access clinical trial management, regulatory affairs and intellectual property. Worked with global companies of various sizes on their strategic assessments and plans as well as specific opportunity assessments in addition to M&A and licensing advisory work. Demonstrated ability to distill scientific and clinical data into commercial value generation and plan program strategy accordingly. Track record reflects a strong history of structuring and completing successful business deals from the perspective of big Pharma (Novartis), as a licensing/M&A consultant to small biotech (Asten BioPharma Advisors), from academia (Mount Sinai) and as an investor (Symphony Capital) providing transactional experience with the insight of various stakeholders. Responsible for prospecting and evaluating hundreds of BD&L/M&A opportunity assessments throughout my career with extensive experience in opportunity identification, asset valuation, financial modeling, deal structure, contract drafting and term negotiations. Successfully negotiated over 150 academic and commercial agreements.

Antidote

Jordan Mayo

Jordan joined Smedvig Capital in 2005 from Bain & Company where he worked on major European buyouts with leading private equity funds. Whilst at Bain he also worked on a wide range of corporate strategy projects for clients in the business services, information technology and manufacturing industries in London and New York. Prior to joining Bain, he was co-founder of revise.it, an online education business. Jordan has a First Class MA in Economics and Management from Oxford University.

Antidote

Name

Francesca Wuttke

Jordan Mayo

Firm

Work History

Broad drug development expertise with over 20 years of commercial, strategic and transactional experience from private equity, management consulting, BD&L and technology licensing and from co-founding Asten BioPharma Advisors, a New York City based healthcare consultancy. PhD in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a BA from Cornell University College of Arts and Sciences. Experience in both science and business has provided proficiency in multiple areas of the pharmaceutical and biotechnology industry including opportunity assessment and selection, product diligence, primary and secondary market research, sales forecasting, market access clinical trial management, regulatory affairs and intellectual property. Worked with global companies of various sizes on their strategic assessments and plans as well as specific opportunity assessments in addition to M&A and licensing advisory work. Demonstrated ability to distill scientific and clinical data into commercial value generation and plan program strategy accordingly. Track record reflects a strong history of structuring and completing successful business deals from the perspective of big Pharma (Novartis), as a licensing/M&A consultant to small biotech (Asten BioPharma Advisors), from academia (Mount Sinai) and as an investor (Symphony Capital) providing transactional experience with the insight of various stakeholders. Responsible for prospecting and evaluating hundreds of BD&L/M&A opportunity assessments throughout my career with extensive experience in opportunity identification, asset valuation, financial modeling, deal structure, contract drafting and term negotiations. Successfully negotiated over 150 academic and commercial agreements.

Jordan joined Smedvig Capital in 2005 from Bain & Company where he worked on major European buyouts with leading private equity funds. Whilst at Bain he also worked on a wide range of corporate strategy projects for clients in the business services, information technology and manufacturing industries in London and New York. Prior to joining Bain, he was co-founder of revise.it, an online education business. Jordan has a First Class MA in Economics and Management from Oxford University.

Other Seats

Antidote

Antidote

Antidote Management Team

6 Team Members

Antidote has 6 executives. Antidote's founder is Eithan Ephrati. Antidote's current Chief Executive Officer is Laurent Schockmel.

Name

Work History

Title

Status

Eithan Ephrati

Founder

Current

Pablo Graiver

Founder

Current

Laurent Schockmel

Truveris, Cegedim, Cegedim Dendrite, Capgemini, IMS Health, and Monsanto

Chief Executive Officer

Current

Keith Lovell

Chief Financial Officer

Current

Kulvinder Maingi

Chief Technology Officer

Current

Name

Eithan Ephrati

Pablo Graiver

Laurent Schockmel

Keith Lovell

Kulvinder Maingi

Work History

Truveris, Cegedim, Cegedim Dendrite, Capgemini, IMS Health, and Monsanto

Title

Founder

Founder

Chief Executive Officer

Chief Financial Officer

Chief Technology Officer

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.